[
    [
        {
            "time": "2018-11-06",
            "original_text": "格隆汇港股聚焦(11.06)︱港交所前三季EBITDA升3%至96.63亿港元 多家券商10月数据亮眼",
            "features": {
                "keywords": [
                    "港交所",
                    "EBITDA",
                    "券商",
                    "10月数据"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(11.06)︱港交所前三季EBITDA升3%至96.63亿港元 多家券商10月数据亮眼",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-11-06",
            "original_text": "国家药监局：政策人才资本都是当前药品创新的利好因素",
            "features": {
                "keywords": [
                    "国家药监局",
                    "政策",
                    "药品创新",
                    "利好因素"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国家药监局：政策人才资本都是当前药品创新的利好因素",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-06",
            "original_text": "一致性评价新进展：这家企业厉害了！",
            "features": {
                "keywords": [
                    "一致性评价",
                    "企业",
                    "进展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "一致性评价新进展：这家企业厉害了！",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-06",
            "original_text": "11月6日股市预警|8家公司突发利空 34亿资金流出这十股",
            "features": {
                "keywords": [
                    "股市预警",
                    "利空",
                    "资金流出"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "11月6日股市预警|8家公司突发利空 34亿资金流出这十股",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-11-06",
            "original_text": "复星医药：控股子公司用于晚期实体瘤治疗药品获临床试验申请受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "临床试验",
                    "晚期实体瘤"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：控股子公司用于晚期实体瘤治疗药品获临床试验申请受理",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-06",
            "original_text": "复星医药(600196.SH)：ORIN1001片用于晚期实体瘤治疗获临床试验注册审评受理",
            "features": {
                "keywords": [
                    "复星医药",
                    "ORIN1001片",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：ORIN1001片用于晚期实体瘤治疗获临床试验注册审评受理",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-06",
            "original_text": "一致性评价铺就中国仿制药提质之路",
            "features": {
                "keywords": [
                    "一致性评价",
                    "仿制药",
                    "提质"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "一致性评价铺就中国仿制药提质之路",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-06",
            "original_text": "169个品种通过一致性评价，有企业过评30个",
            "features": {
                "keywords": [
                    "一致性评价",
                    "品种",
                    "企业"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "169个品种通过一致性评价，有企业过评30个",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-06",
            "original_text": "【晨会聚焦】超配金融板块",
            "features": {
                "keywords": [
                    "晨会聚焦",
                    "金融板块",
                    "超配"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【晨会聚焦】超配金融板块",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-11-05",
            "original_text": "【医药-复星医药(600196)】江琦、赵磊：公司点评：Grand计划推进海外上市，生物药、小分子创新持续",
            "features": {
                "keywords": [
                    "复星医药",
                    "Grand计划",
                    "海外上市",
                    "生物药",
                    "小分子创新"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药-复星医药(600196)】江琦、赵磊：公司点评：Grand计划推进海外上市，生物药、小分子创新持续",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]